Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of LY3154885 in Healthy Subjects
NCT04014361Phase 1Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2019
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LY3154885 in Alzheimer's disease (AD), Lewy body dementia (LBD) and Parkinson's disease dementia (PDD) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration up to 5 months. Started Aug 2019; status: terminated.
02
Drugs
LY3154885
03
Conditions
Alzheimer's disease (AD)Lewy body dementia (LBD)Parkinson's disease dementia (PDD)
Beyond the preview
Go deeper on NCT04014361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04014361.